Fluidigm Corporation has announced that it will unveil a commercially available system for high-parameter tissue imaging on Tuesday, October 24, 2017, via a global livestream video.
This new imaging system significantly expands the number of protein biomarkers that can be simultaneously detected from tissues and tumors as compared to results from standard fluorescent immunohistochemistry methods. With the potential to revolutionize disease research and change the way diseases are treated and ultimately cured in the future, this new approach provides researchers with an unprecedented view of complex cellular phenotypes and their relationships in the context of the tissue microenvironment.
We invite our colleagues from across the life science industry to join us online at fluidigm.com/futureofimaging for a unique view into the potential of this new technology on Tuesday, October 24, 2017, at 7:00 a.m. PT (10:00 a.m. ET).
Come see the future of imaging
The program will include live presentations by Chris Linthwaite, President and CEO of Fluidigm, and leading scientists who will share their insights and experiences with this revolutionary new approach to tissue imaging.
"I am very excited to empower members of the global research community with this innovative new system and enable them to transform our understanding of life, leading to the development of better diagnostics and more effective therapies in the future," said Linthwaite. "Join us for this exciting event on the 24th and hear firsthand about the next frontier in tissue imaging."
The program will be available via livestream video from the InterContinental Toronto Centre, Toronto, Canada. A link to the webcast will not be active until 6:45 a.m. PT (9:45 a.m. ET) on October 24, 2017. A video replay of the live webcast will be available 120 minutes after the end of the meeting at fluidigm.com/futureofimaging and will be archived on fluidigm.com.